Full Fed. Circ. Won't Undo Sandoz Loss In Patent Fight
The full Federal Circuit on Tuesday refused Sandoz Inc.'s request to reconsider a panel decision that had upheld two patents covering Amgen's top-selling biologic Enbrel....To view the full article, register now.
Already a subscriber? Click here to view full article